Tuesday, February 15, 2022
4:00PM – 5:00PM ET
Please note this TeleECHO program is 4:00PM Eastern, 3:00PM Central, 2:00PM Mountain and 1:00PM Pacific.
PROGRAM OVERVIEW
These live virtual TeleECHO® sessions will be a faculty-led didactic and case-based lecture focusing on the management of patients with endometrial cancer.
Presenting Faculty:
Ursula A. Matulonis, M.D.
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Learning Objectives
After completing the CME activity, learners should be better able to:
- Critique the rationale supporting the biological features of EC that make it an attractive candidate for the use of immuno-oncology therapies
- Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with advanced EC
- Devise strategies to manage the irAEs and trAEs associated IO/TKI combination therapies in development for patients with advanced EC
- Support multidisciplinary care teams for the management of patients with EC
Target Audience
This activity is intended for U.S.-based gynecologic oncologists, medical oncologists, obstetrician/gynecologists and other healthcare providers involved in the treatment of gynecologic cancers including endometrial cancer.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the management of patients with endometrial cancer.
CNE Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
